Anti-SARS-CoV-1, Spike (Clone COV1-100) – Purified No Carrier Protein
Anti-SARS-CoV-1, Spike (Clone COV1-100) – Purified No Carrier Protein
Product No.: S1005
- -
- -
Product No.S1005 Clone COV1-100 Target SARS-CoV-1 ⋅ Spike Formats AvailableView All Product Type Recombinant Monoclonal Antibody Alternate Names SARS, S2 protein, Spike glycoprotein 2 Isotype Human IgG1λ |
- -
- -
Antibody DetailsProduct DetailsReactive Species SARS-CoV-1 Expression Host HEK-293 Cells Immunogen Sequenced from PBMCs from a donor who had recovered from a naturally-occurring SARS infection. Product Concentration ≥1.0 mg/ml Purity ≥90% monomer by analytical SEC and SDS-Page Formulation This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -80°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2 – 8° C Wet Ice Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity COV1-100 targets the prefusion spike protein (S2) of SARS-CoV-1 and SARS-CoV-
2. Background SARS-CoV-1, also known as the Severe Acute Respiratory Syndrome coronavirus, is a zoonotic
virus that is believed to have originated from an animal reservoir, possibly horseshoe bats, and
transmitted to humans1. This virus primarily affects the respiratory system and can cause
symptoms such as muscle pain, headache, fever, cough, dyspnea, and pneumonia1,2. It was the
first severe and readily transmissible new disease to emerge in the 21st century, with the
capacity to spread globally via international air travel. The COV1-100 monoclonal antibody targets the spike protein of both SARS-CoV-1 and SARS- CoV-2, demonstrating cross-reactivity. However, it does not block the ACE2 receptor and does not function as a neutralizer. The epitope targeted by COV1-100 is unknown, which indicates that more research is needed to determine its binding site and potential role in viral inhibition. Despite not being a neutralizer, COV1-100 might play a role in modulating the immune response or could be useful in combination with other antibodies that have neutralizing capabilities, providing a broader spectrum of antiviral activity. Antigen Distribution Anti-SARS-CoV-1 recognizes antigens on infected cells, including
respiratory epithelial cells. NCBI Gene Bank ID UniProt.org Research Area Category C Pathogens . Infectious Disease . Viral . IVD Raw Material References & Citations1. Mann R, Perisetti A, Gajendran M, Gandhi Z, Umapathy C, Goyal H. Clinical Characteristics, Diagnosis, and Treatment of Major Coronavirus Outbreaks. Front Med (Lausanne). 2020;7:581521. 2. Rat P, Olivier E, Dutot M. SARS-CoV-2 vs. SARS-CoV-1 management: antibiotics and inflammasome modulators potential. Eur Rev Med Pharmacol Sci. 2020;24(14):7880-7885. |
Formats Available
- -
- -
Prod No. | Description |
---|---|
S1005 |
